Evidence map›Paper›PMID 32134978›Full record

Trial reportPloS one2020

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.

Zongwei Wang, Tuo Deng, Xingbo Long, Xueming Lin, Shulin Wu, Hongbo Wang, Rongbin Ge, Zhenwei Zhang, Chin-Lee Wu, Mary-Ellen Taplin and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01393730 (Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01393730 phase2completednot on this map

Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression

TypeinterventionalSponsorMary-Ellen Taplin, MDRan2011 to 2017Enrolled40ConditionsProstate CancerArmsAbiraterone acetate, Dutasteride, Prednisone
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Ectonucleotidases and purinergic receptors in mouse prostate gland.American journal of clinical and experimental urology · 2025
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Zongwei WangDepartment of Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.ORCID 0000-0002-1215-2912
Tuo DengDepartment of Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
Xingbo LongDepartment of Urology, Union Medical College, Beijing, China.
Xueming LinDepartment of Pathology and Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.
Shulin WuDepartment of Pathology and Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.
Hongbo WangDepartment of Pathology and Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.
Rongbin GeDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, United States of America.
Zhenwei ZhangDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America.
Chin-Lee WuDepartment of Pathology and Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.
Mary-Ellen TaplinDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America.
Aria F OlumiDepartment of Surgery, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.
Harvard University · USBeth Israel Deaconess Medical Center · USChinese Academy of Medical Sciences & Peking Union Medical College · CNUniversity of Massachusetts Chan Medical School · US

Funding

Reduced Levels of 5-alpha Reductase 2 in Adult Prostate Tissue: Implications forR01DK091353 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI OLUMI, ARIA F · 2011 to 2015
$1.9M
NIDDK NIH HHS R01 DK091353
6 · The paper itself

Abstract

purposeTo determine whether SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in CRPC. PATIENTS AND

methodsIn a Local CRPC cohort, 42 prostatic specimens were collected from patients who were diagnosed as CRPC and underwent transurethral resection of the prostate (TURP) at Massachusetts General Hospital (MGH). In a metastatic CRPC (Met CRPC) cohort, 12 metastatic biopsies were collected from CRPC patients who would be treated with abiraterone plus dutasteride (Clinical Trial NCT01393730). As controls, 36 benign prostatic specimens were collected from patients undergoing prostate reduction surgery for symptoms of bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). The methylation status of cytosine-phosphate-guanine (CpG) site(s) at SRD5A2 promoter regions was tested.

resultsCompared with benign prostatic tissue, CRPC samples demonstrated higher SRD5A2 methylation in the whole promoter region (Local CRPC cohort: P < 0.001; Met CRPC cohort: P <0.05). In Local CRPC cohort, a higher ratio of methylation was correlated with better OS (R2 = 0.33, P = 0.013). Hypermethylation of specific regions (nucleotides -434 to -4 [CpG# -39 to CpG# -2]) was associated with a better OS (11.3±5.8 vs 6.4±4.4 years, P = 0.001) and PFS (8.4±5.4 vs 4.5±3.9 years, P = 0.003) with cutoff value of 37.9%. Multivariate analysis showed that SRD5A2 methylation was associated with OS independently (whole promoter region: P = 0.035; specific region: P = 0.02).

conclusionOur study demonstrate that SRD5A2 methylation in promoter regions, specifically at CpG# -39 to -2, is significantly associated with better survival for CRPC patients treated with ADT. Recognition of epigenetic modifications of SRD5A2 may affect the choices and sequence of available therapies for management of CRPC.

Indexed as

3-Oxo-5-alpha-Steroid 4-Dehydrogenase5-alpha Reductase InhibitorsAndrostenesDNA MethylationDutasterideEpigenesis, GeneticHumansMaleMembrane ProteinsPrognosisPromoter Regions, GeneticProstatic Neoplasms, Castration-ResistantTreatment Outcome3-Oxo-5-alpha-Steroid 4-Dehydrogenase5-alpha Reductase InhibitorsabirateroneAndrostenesDutasterideMembrane ProteinsSRD5A2 protein, human

Identifiers

PMID32134978
PMCPMC7058338
OpenAlexW3009076554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.